Sufficiently important difference: Expanding the framework of clinical significance

Medical Decision Making

Volumn 25, Issue 3, 2005, Pages 250-261

  Barrett, Bruce ^a,b   Brown, David ^a   Mundt, Marlon ^a   Brown, Roger ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Department of Family Medicine ^*  (United States)

Author keywords

Clinical significance; Clinical trials; Evidence based medicine; Health status; Important difference; Outcome measures; Patient oriented medicine; Quality of life; Treatment outcome

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH SERVICE; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; MINIMAL IMPORTANT DIFFERENCE; OUTCOMES RESEARCH; PUBLIC HEALTH; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SUFFICIENTLY IMPORTANT DIFFERENCE; TREATMENT OUTCOME;

ATTITUDE TO HEALTH; BENCHMARKING; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; INFORMED CONSENT; PAIN MEASUREMENT; PATIENT SELECTION; PATIENT-CENTERED CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 18844409426     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05276863     Document Type: Article

References (90)

1. Balint E. The possibilities of patient-centered medicine. J R Coll Gen Pract. 1969;17(82):269-76.
2. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129-36.
3. Laine C, Davidoff F. Patient-centered medicine. A professional evolution. JAMA. 1996;275(2):152-6.
4. Guyatt GH, Rennie D. Users' Guides to the Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press; 2002.
5. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingstone; 2000.
6. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston: Butterworth-Heinemann; 1988.
7. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-15.
8. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
9. Institute of Medicine, National Academy of Sciences, National Academy of Engineering, and National Research Council. U.S. Health Care Delivery System Needs Major Overhaul to Improve Quality and Safety. 1-6. 3-1-2001. Washington, DC: National Academy Press; 2001.
10. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. Oxford, UK: Oxford University Press; 1996.
11. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press; 1997.
12. Rhoads S. Opportunity Cost. The Economist's View of the World. New York: Cambridge University Press; 1985.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
14. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211:453-8.
15. Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nursing Res. 1997;29:45-64.
16. Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions. Cognitive and emotional perspectives. JAMA. 1993;270:72-6.
17. Llewellyn-Thomas HA. Patients' health-care decision making: a framework for descriptive and experimental investigations. Med Decis Making. 1995;15:101-6.
18. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol. 1994;47:787-95.
19. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54:253-62.
20. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ; 2001.
21. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York: Springer-Verlag; 1998.
22. Albert JM, DeMets DL. On a model-based approach to estimating efficacy in clinical trials. Stat Med. 1994;13:2323-35.
23. Gong J, Pinheiro JC, DeMets DL. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control Clin Trials. 2000;21:313-29.
24. Kazis LE, Anderson JL, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(suppl):S178-89.
25. Naughton MJ, Shumaker SA. Assessment of health-related quality of life. In: Friedman LM, Furberg CD, DeMets DL, eds. Fundamentals of Clinical Trials. New York: Springer-Verlag; 1998. p 185-203.
26. Deyo RA, Patrick DL. The significance of treatment effects: the clinical perspective. Med Care. 1995;33:AS286-91.
27. Beaton DE, Bombardier C, Katz JN, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol. 2001;28:400-5.
28. Bruynesteyn K, van der HD, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthr Rheum. 2002;46:913-20.
29. Lassere MN, van der HD, Johnson KR. Foundations of the minimal clinically important difference for imaging. J Rheumatol. 2001;28:890-1.
30. Samsa G. How should the minimum important difference for a health-related quality-of-life instrument be estimated? Med Care. 2001;39:1037-8.
31. Lassere MND, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol. 2001;28:892-903.
32. Beckerman H, Roebroeck ME, Lankhorst GJ, Becher JG, Bezemer PD. Smallest real difference, a link between reproducibility and responsiveness. Qual Life Res. 2001;10:571-8.
33. Bombardier C, Hayden J, Beaton DE. Minimal clinically important difference, low back pain: outcomes measures. J Rheumatol. 2001;28:431-8.
34. Brant R, Sutherland L, Hilsden R. Examining the minimum important difference. Stat Med. 1999;18:2593-603.
35. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39:1039-47.
36. Charon R. The patient-physician relationship. Narrative medicine: a model for empathy, reflection, profession and trust. JAMA. 2001;286:1897-902.
37. Henbest RJ, Fehrsen GS. Patient-centredness: is it applicable outside of the West? Its measurement and effect on outcomes. Fam Pract. 1992;9:311-7.
38. Law S, Britten N. Factors that influence the patient centredness of a consultation. Br J Gen Pract. 1995;45:520-4.
39. Roter DL, Hall JA. Doctors Talking with Patients: Patients Talking with Doctors: Improving Communication in Medical Visits. Westport, CT: Auburn House; 1992.
40. Stewart MA, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. 2000;49:796-804.
41. Chewning B, Sleath B. Medication decision-making and management: a client-centered model. Soc Sci Med. 1996;42:389-98.
42. Guadagnoli E, Ward P. Patient participation in decision-making. Soc Sci Med. 1998;47:329-39.
43. Mansell D, Poses RM, Kazis L, Duefield CA. Clinical factors that influence patients' desire for participation in decisions about illness. Arch Intern Med. 2000;160:2991-6.
44. Bennett J. What does the consumer want in the consultation relationship? Aust J Med Herbal. 1999;11:16-20.
45. Doescher MP, Saver BG, Franks P, Fiscella K. Racial and ethnic disparities in perceptions of physician style and trust. Arch Fam Med. 2000;9:1156-63.
46. Goldberg PE. The physician-patient relationship: three psychodynamic concepts that can be applied to primary care. Arch Fam Med. 2000;9:1164-8.
47. Latham CE. Is there data to support the concept that educated, empowered patients have better outcomes? J Am Soc Nephrol. 1998;9:Suppl-4.
48. McKnight JL. Health and empowerment. Can J Public Health. Revue Canadienne de Sante Publique. 1985;76:Suppl-8.
49. Kleinman A. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978;88:251-8.
50. Kleinman A. Why psychiatry and cultural anthropology still need each other. Psychiatry. 2001;64:14-6.
51. Beurs E, Wilson KA, Chambless DL, Goldstein AJ, Feske U. Convergent and divergent validity of the Beck anxiety inventory for patients with panic disorder and agoraphobia. Depress Anxiety. 1997;6:140-6.
52. Kuzel AJ. Naturalistic inquiry: an appropriate model for family medicine. Fam Med. 1986;18:369-74.
53. Long AF, Mercer G, Hughes K. Developing a tool to measure holistic practice: a missing dimension in outcomes measurement within complementary therapies. Comp Ther Med. 2000;8:26-31.
54. Miller WL. Models of health, illness, and health care. In: Buckingham JL, Donatelle EP, Johnson TA, Scherger JE, eds. Family Medicine: Principles and Practice. New York: Springer-Verlag; 1988. p 35-42.
55. Stephens GG. The intellectual basis of family practice. J Fam Pract. 1975;2:423-8.
56. Angell M. Patients' preferences in randomized clinical trials. N Engl J Med. 1984;310:1385-7.
57. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ. 1989;299:313-5.
58. Kaplan RM. Human preference measurement for health decisions and the evaluation of long-term care. In: Kane R, ed. Value in Long Term Care. Lanham, MD: Lexington Books; 1982. p 157-88.
59. Cook KF, Ashton CM, Byrne MM, et al. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc Sci Med. 2001;53:1275-85.
60. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-83.
61. Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative importance in preference based outcome measures. Qual Life Res. 1993;2:467-75.
62. Martin AJ, Glasziou PP, Simes RJ, Lumley T. A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int J Technol Assess Health Care. 2000;16:137-47.
63. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Operat Res. 1982;30(6):1043-69.
64. Barthelemy JP, Mullet E. Choice basis: a model for multi-attribute preference. Br J Math Stat Psychol. 1986;39(Pt 1):106-24.
65. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res. 1999;8(3):171-80.
66. Schapira MM, Gilligan MA, McAuliffe TL, Nattinger AB. Menopausal hormone therapy decisions: insights from a multi-attribute model. Patient Educ Counsel. 2004;52(1):89-95.
67. Jaeschke R, Guyatt GH, Keller J, Singer J. Interpreting changes in quality-of-life score in N of 1 randomized trials. Control Clin Trials. 1991;12:Suppl-233S.
68. vanWalraven C, Mahon JL, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample-size calculation. J Clin Epidemiol. 1999;52:717-23.
69. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-7.
70. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14:23-7.
71. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-44.
72. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? BJOG: Int J Obstet Gynaecol. 2004;111(6):605-12.
73. Ringash J, Bezjak A, O'Sullivan B, Redelmeier DA. Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients. Qual Life Res. 2004;13(4):725-33.
74. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557-60.
75. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49:1215-9.
76. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14:109-14.
77. Redelmeier DA, Guyatt GH, Goldstein RS. On the debate over methods for estimating the clinically important difference. J Clin Epidemiol. 1996;49:1223-4.
78. Wells G, Anderson J, Beaton D, et al. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol. 2001;28:452-4.
79. Powell CV, Kelly A-M. Determining the minimum clinically significant difference in visual analog pain score for children. Ann Emerg Med. 2001;37:28-31.
80. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287-94.
81. Bruynesteyn K, van der HD, Boers M, et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol. 2001;28:904-10.
82. Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med. 1996;3:142-6.
83. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21:267-72.
84. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003;56:248-55.
85. Burback D, Molnar FJ, St John P, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cognit Disord. 1999;10:534-40.
86. Wyrwich KW, Nelson HS, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel report. Ann Allergy Asthma Immunol. 2003;91:148-53.
87. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med. 2003;18:196-202.
88. Wyrwich KW, Spertus JA, Kroenke K, et al. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147(4):615-22.
89. Barrett B, Brown RL, Mundt MP, et al. Using benefit harm trade-offs to estimate sufficiently important difference: the case of the common cold. Med Decis Making. 2005;25:47-55.
90. von Neumann J, Morgenstern O. Theories of Games and Economic Behavior. Princeton, NJ: Princeton University Press; 1947.